100-mg Scored Tablets and
300-mg Scored Tablets
ZYLOPRIM is a xanthine oxidase inhibitor which is administered orally. Each scored white tablet contains 100 mg allopurinol and each scored peach tablet contains 300 mg allopurinol.
THIS IS NOT AN INNOCUOUS DRUG. IT IS NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA.
ZYLOPRIM reduces serum and urinary uric acid concentrations. Its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics (see CLINICAL PHARMACOLOGY, CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS).
ZYLOPRIM is indicated in:
- the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy).
- the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment with ZYLOPRIM should be discontinued when the potential for overproduction of uric acid is no longer present.
- the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. Therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks.
Media Articles Related to Zyloprim (Allopurinol)
Gout: data from Phase III studies of lesinurad in combination with allopurinol
Source: Gout News From Medical News Today [2014.11.19]
AstraZeneca has presented top-line results of two pivotal Phase III trials investigating the potential of lesinurad, a selective uric acid re-absorption inhibitor (SURI), when used in combination...
Less than half of gout patients reach recommended treatment goal following treatment with allopurinol
Source: Gout News From Medical News Today [2013.10.31]
AstraZeneca and Ardea Biosciences presented results from a large study of allopurinol, a treatment commonly used to lower uric acid in patients with gout.
Gout drug may reduce risk of death
Source: Gout News From Medical News Today [2014.03.26]
In a recently to be published study in Annals of the Rheumatic Diseases, researchers have found the use of the drug allopurinol was associated with a reduced risk of death in hyperuricemic (gout)...
Anakinra an Effective Option in Complex Gout (CME/CE)
Source: MedPage Today Psychiatry [2015.03.13]
(MedPage Today) -- Acutely ill patients with contraindications to NSAIDs may benefit from this therapy.
Gout Comorbities and Costs Climb (CME/CE)
Source: MedPage Today Nephrology [2015.03.12]
(MedPage Today) -- Greater direct and indirect costs incurred for older and treatment-refractory patients.
Published Studies Related to Zyloprim (Allopurinol)
Allopurinol reduces left ventricular mass in patients with type 2 diabetes and
left ventricular hypertrophy. 
regression of LVH in patients with T2DM... CONCLUSIONS: Allopurinol causes regression of LVM in patients with T2DM and LVH.
High-dose allopurinol reduces left ventricular mass in patients with ischemic
heart disease. 
to reduce LV afterload in IHD and may therefore also regress LVH... CONCLUSIONS: High-dose allopurinol regresses LVH, reduces LV end-systolic volume,
Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris. [2011.08.16]
OBJECTIVES: The aim of this study was to evaluate the effect of high-dose allopurinol on vascular oxidative stress (OS) and endothelial function in subjects with stable coronary artery disease (CAD). BACKGROUND: Allopurinol, a xanthine oxidase inhibitor, prolongs the time to chest pain during exercise in angina. We sought to ascertain whether allopurinol also improves endothelial dysfunction in optimally treated CAD patients, because such an effect might be of value to reduce future cardiovascular mortality. The mechanism of the anti-ischemic effect of allopurinol could be related to its reducing xanthine oxidase-induced OS, and our second aim was to see whether allopurinol really does reduce vascular tissue OS in CAD patients... CONCLUSIONS: Our study demonstrates that, in optimally treated CAD patients, high-dose allopurinol profoundly reduces vascular tissue OS and improves 3 different measures of vascular/endothelial dysfunction. The former effect on OS might underpin the anti-ischemic effect of allopurinol in CAD. Both effects (on OS and endothelial dysfunction) increase the likelihood that high-dose allopurinol might reduce future cardiovascular mortality in CAD, over and above existing optimum therapy. (Exploring the therapeutic potential of xanthine oxidase inhibitor allopurinol in angina; ISRCTN15253766). Copyright (c) 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. [2011.07]
Allopurinol ameliorates endothelial dysfunction and arterial stiffness among patients without chronic kidney disease (CKD), but it is unknown if it has similar effects among patients with CKD.Because LVH and endothelial dysfunction associate with prognosis, these results call for further trials to examine whether allopurinol reduces cardiovascular events in patients with CKD and LVH.
Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. [2011.07]
OBJECTIVE: This study assessed the efficacy and safety of canakinumab, a fully human anti-interleukin 1beta monoclonal antibody, for prophylaxis against acute gouty arthritis flares in patients initiating urate-lowering treatment... CONCLUSIONS: Single canakinumab doses >/=50 mg or four 4-weekly doses provided superior prophylaxis against flares compared with daily colchicine 0.5 mg.
Clinical Trials Related to Zyloprim (Allopurinol)
Allopurinol for Mania: A Randomized Trial Administering Allopurinol vs. Placebo as add-on to Mood Stabilizers and/or Antipsychotics in Patients in a Bipolar Manic Episode [Recruiting]
The objective of the study is to evaluate the efficacy of allopurinol, compared to placebo,
as add-on to mood stabilizers and/or antipsychotic in the treatment of patients with bipolar
disorder, in a manic episode.
Allopurinol Combination Study [Recruiting]
To compare the proportion of subjects whose serum urate (sUA) levels are < 6. 0 mg/dL
following 4 weeks of continuous treatment of RDEA594 in combination with allopurinol to
allopurinol alone in subjects with documented inadequate hypouricemic response with standard
doses of allopurinol.
Azathioprine & Allopurinol in Inflammatory Bowel Disease Patients [Recruiting]
Allopurinol Outcome Study [Recruiting]
This is a study of allopurinol in gout patients with hyperuricemia that will evaluate the
safety and serum urate (sUA) lowering capability of allopurinol as a urate lowering therapy
(ULT) for up to six months. Allopurinol will be dosed according to the local product label,
at the discretion of the Investigator, to achieve an optimal, medically appropriate dose for
Effectiveness Allopurinol Topical Agent Prevention Capecitabine-induced Hand-foot Syndrome [Recruiting]
Hand-foot syndrome (HFS) is a dose-limiting toxicity of capecitabine for which no effective
preventative treatment has been definitively demonstrated. This trial is conducted on the
basis of preliminary data that a 3% allopurinol-based topical agent may prevent HFS.
A randomized, double-blind phase III trial will evaluate 40 patients receiving their first
ever cycle of capecitabine at a dose of either 2,000 or 2,500 mg/m2 per day for 14 days.
Patients will be randomly assigned to a 3% allopurinol versus a placebo cream, which will be
applied to the hands and feet twice per day for 6 months after the start of capecitabine.
Patients will be examined every month and the investigators will take some photographs of
hands and feet. HFS toxicity grade (Common Terminology Criteria for Adverse Events
[CTCAE]v3. 0) will be also collected at baseline and at the end of each cycle. The primary
end point is the incidence of moderate/severe HFS symptoms at the end of capecitabine
treatment , based on the patient-reported dermatological exploration.